Download by
Scanning QR Code
No Stock Yet
CITIC Construction Investment: Medical and aesthetic demand will gradually recover, leading companies are resilient
Changes in the beauty care sector boosted Bethenny's rise by more than 5%
Caixin Securities: Consumer demand is expected to bottom up and the valuation of the beauty care sector is the most cost-effective
The Zhitong Finance App learned that Caixin Securities released a research report saying that looking ahead to next year, the relaxation of the epidemic prevention policy is combined with strategies to expand domestic demand, and domestic consumer demand is expected to bottom up and rise. Looking at the industry level, loosening expectations of epidemic prevention boosted the sector's rise. The three major sectors of beauty care, social services, and commercial retail all performed well. Under the impact of the epidemic in 2022, the social services sector's performance improved the most. Currently, the valuation of the beauty care sector is the most cost-effective. In the beauty care sector, trends in the cosmetics industry have been improving for a long time. On the performance side, internal performance is divided, and the certainty of leading core companies continues to be realized. Investment advice: Focus on recommending Aimei
Concept tracking | The recovery of offline traffic has become the greatest strength in medicine and beauty! Institutions: Downstream service agencies are more elastic upward (with concept stocks)
The Zhitong Finance App learned that the resumption of the epidemic is compounded by marginal easing of epidemic prevention policies, and medical aesthetics as offline consumption is expected to continue to recover. The agency pointed out that medical and aesthetic products need to reach consumers through downstream and offline service agencies. With the marginal relaxation of epidemic prevention and control, the backlog of medical and aesthetic demand is expected to be released and drive a rebound in the market. In particular, light medicine and aesthetics are curative and are expected to show greater flexibility. From the perspective of the industrial chain, downstream service agencies were the most severely damaged during the pandemic and were more resilient upward in the recovery channel. According to Ai media consultation data, nearly 60% of people in our country have an understanding of light medicine and aesthetic consumption, and nearly 80% of people say they are willing to try light medicine in the f
Changes in the beauty care sector boosted Guangzhou Langqi by more than 5%
Imeike (300896.SZ) and its subsidiaries plan to use no more than 3 billion yuan of idle own funds for entrusted financial management
On December 13, Gelonghui (300896.SZ) announced that the company held the second meeting of the third board of directors on December 13, 2022, and passed the “Proposal on the Company's Use of Idle Own Funds for Entrusted Financial Management”. Without affecting the normal development of the main business and ensuring operating capital requirements and capital safety, the company and its subsidiaries intend to use a maximum amount of no more than 3 billion yuan of idle own funds for entrusted financial management. This time, entrusted financial management is limited to the purchase of highly secure and liquid structured deposits, large deposit notes, agreement deposits or notification deposits, fixed income types, or fixed income types, or
Emick (300896): revenue-side growth bright new product sales continue to improve
The event description company announced that in the third quarter of 2022, the company achieved operating income of 605 million yuan, an increase of 55.15% over the same period last year, a net profit of 401 million yuan, an increase of 41.55%, and a non-return net profit of 395 million yuan, an increase of 52.26% over the same period last year. Event comments as personal consumption + local consumption + selective consumption, the company's revenue resumed as scheduled in the third quarter. The company's revenue growth slowed sharply in the second quarter affected by the epidemic. Under the background of the overall offline epidemic easing in the third quarter, the company's revenue side quickly recovered to 5.
Emick (300896): 22Q3 revenue YOY+55.15% high net worth products accumulate abruptly to drive the overall higher-than-expected endogenous epitaxy to build core barriers
The company released three quarterly reports in 2022, 2022Q1-3 revenue of 1.489 billion yuan, yoy+45.58%; return net profit of 992 million yuan, yoy+39.96%; deduction of non-return net profit of 965 million yuan, yoy+44.06%. Of this total, the operating income of 22Q3 was 605 million yuan, the net profit of yoy+55.15%; was 401 million yuan, and the net interest rate of yoy+41.55%, was 66.37%, which also decreased 6.38pct, mainly due to changes in fair value such as transactional financial assets in the same period last year.
Emick (300896) comments: the third quarter results slightly exceeded expectations Angel needle double to achieve the second curve
Investment points: the company announced the third quarterly report of 2022, the performance slightly exceeded expectations. 1) 22Q1-3 realized revenue of 1.49 billion yuan, an increase of 45.6% over the same period last year, and net profit of 990 million yuan, an increase of 40% over the same period last year, deducting 970 million yuan of non-return net profit, an increase of 44.1% over the same period last year. 2) 22Q3 achieved revenue of 600 million yuan in a single quarter, an increase of 55.2% over the same period last year, and net profit of 400 million yuan, an increase of 41.6% over the same period last year, deducting 390 million yuan of non-return net profit, an increase of 52.3% over the same period last year. The performance in the third quarter slightly exceeded expectations, compared with the previous quarter.
Comment on the third quarterly report of Emick (300896) 2022: the growth rate of a single quarter increases and is optimistic about the high growth of the whole year.
Guide to this report: with the decrease in the impact of the epidemic in the third quarter, the core products and your needle terminals continue to release volume during the day, the profitability is significant under the product competitive advantage, and the multi-pipeline differentiated product matrix helps to boost the long-term growth space and maintain the overweight rating. Key points of investment: maintain the overweight rating. 2022Q1-3 realized revenue of 1.489 billion yuan (+ 45.58%), net profit of 992 million yuan (+ 39.96%), net profit of 965 million yuan (+ 44.06%) and revenue of 6.05 yuan in the third quarter.
Loading...
No Stock Yet